Omega Therapeutics, Inc. (OMGA)

NASDAQ: OMGA · IEX Real-Time Price · USD
10.66 0.43 (4.20%)
Jan 14, 2022 4:00 PM EST - Market closed
Market Cap509.28M
Revenue (ttm)n/a
Net Income (ttm)-56.89M
Shares Out47.77M
EPS (ttm)-5.03
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume55,982
Open10.16
Previous Close10.23
Day's Range9.51 - 10.78
52-Week Range9.51 - 31.41
Betan/a
AnalystsBuy
Price Target29.50 (+176.7%)
Earnings Daten/a

About OMGA

At Omega Therapeutics, our goal is to pioneer a new class of DNA-sequence-targeting, mRNA-encoded therapeutics to fundamentally transform human medicine in the service of patients. Our pioneering OMEGA Epigenomic Programming platform is designed to coopt nature’s universal operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. We rationally design and engineer modular, programmable mRNA-encoded epigenetic medicines, which we call Omega Epigenomic Controllers, or OECs, to target DNA-se...

IndustryBiotechnology
IPO DateJul 30, 2021
CEOMahesh Karande
Employees60
Stock ExchangeNASDAQ
Ticker SymbolOMGA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for OMGA stock is "Buy." The 12-month stock price forecast is 29.50, which is an increase of 176.74% from the latest price.

Price Target
$29.50
(176.74% upside)
Analyst Consensus: Buy

News

Omega Therapeutics Announces Appointment of Yan Moore, M.D., as Chief Medical Officer

CAMBRIDGE, Mass., Jan. 10, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeu...

5 days ago - PRNewsWire

Omega Therapeutics to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

CAMBRIDGE, Mass., Nov. 18, 2021 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeu...

1 month ago - PRNewsWire

Omega Therapeutics Reports Third Quarter 2021 Financial Results and Outlines Key Corporate Objectives

CAMBRIDGE, Mass., Nov. 10, 2021 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeu...

2 months ago - PRNewsWire

Omega Therapeutics to Present at the Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 9, 2021 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeut...

2 months ago - PRNewsWire

Omega Therapeutics Announces Strategic Research Collaboration with Stanford University School of Medicine

CAMBRIDGE, Mass., Oct. 14, 2021 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeu...

3 months ago - PRNewsWire

Omega Therapeutics to Present at the Chardan Virtual 5th Annual Genetic Medicines Conference

CAMBRIDGE, Mass., Sept. 27, 2021 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therape...

3 months ago - PRNewsWire

Omega Therapeutics Reports Second Quarter 2021 Financial Results and Outlines Key Corporate Objectives

CAMBRIDGE, Mass., Sept. 10, 2021 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therape...

4 months ago - PRNewsWire

Omega Therapeutics Kicks Start Trading On NASDAQ

On the heels of a $126 million crossover round in March, Flagship Pioneering-backed Omega Therapeutics Inc (NASDAQ: OMGA) has priced a $125.8 million IPO to take its "epigenomic controllers" into the cl...

5 months ago - Benzinga

Omega Therapeutics Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass, July 29, 2021 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company leveraging its OMEGA Epigenomic Programming™ platform to harne...

5 months ago - PRNewsWire